CRNX
Price
$37.46
Change
+$0.60 (+1.63%)
Updated
Feb 21 closing price
Capitalization
3.47B
5 days until earnings call
REGN
Price
$700.33
Change
+$4.31 (+0.62%)
Updated
Feb 21 closing price
Capitalization
76.56B
68 days until earnings call
Ad is loading...

CRNX vs REGN

Header iconCRNX vs REGN Comparison
Open Charts CRNX vs REGNBanner chart's image
Crinetics Pharmaceuticals
Price$37.46
Change+$0.60 (+1.63%)
Volume$928.93K
Capitalization3.47B
Regeneron Pharmaceuticals
Price$700.33
Change+$4.31 (+0.62%)
Volume$727.44K
Capitalization76.56B
CRNX vs REGN Comparison Chart
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. REGN commentary
Feb 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Hold and REGN is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 22, 2025
Stock price -- (CRNX: $36.86 vs. REGN: $696.02)
Brand notoriety: CRNX: Not notable vs. REGN: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 64% vs. REGN: 60%
Market capitalization -- CRNX: $3.47B vs. REGN: $76.56B
CRNX [@Biotechnology] is valued at $3.47B. REGN’s [@Biotechnology] market capitalization is $76.56B. The market cap for tickers in the [@Biotechnology] industry ranges from $369.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • REGN’s FA Score: 1 green, 4 red.
According to our system of comparison, REGN is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 5 TA indicator(s) are bullish while REGN’s TA Score has 3 bullish TA indicator(s).

  • CRNX’s TA Score: 5 bullish, 4 bearish.
  • REGN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CRNX is a better buy in the short-term than REGN.

Price Growth

CRNX (@Biotechnology) experienced а +4.54% price change this week, while REGN (@Biotechnology) price change was +3.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.57%. For the same industry, the average monthly price growth was +3.87%, and the average quarterly price growth was +3.11%.

Reported Earning Dates

CRNX is expected to report earnings on May 08, 2025.

REGN is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (+4.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($76.6B) has a higher market cap than CRNX($3.47B). REGN YTD gains are higher at: -2.164 vs. CRNX (-27.909). REGN has higher annual earnings (EBITDA): 5.32B vs. CRNX (-304.51M). CRNX has less debt than REGN: CRNX (52.5M) vs REGN (2.7B). REGN has higher revenues than CRNX: REGN (14.2B) vs CRNX (1.04M).
CRNXREGNCRNX / REGN
Capitalization3.47B76.6B5%
EBITDA-304.51M5.32B-6%
Gain YTD-27.909-2.1641,290%
P/E RatioN/A18.27-
Revenue1.04M14.2B0%
Total Cash863MN/A-
Total Debt52.5M2.7B2%
FUNDAMENTALS RATINGS
CRNX vs REGN: Fundamental Ratings
CRNX
REGN
OUTLOOK RATING
1..100
6812
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
3
Undervalued
PROFIT vs RISK RATING
1..100
5347
SMR RATING
1..100
9654
PRICE GROWTH RATING
1..100
8364
P/E GROWTH RATING
1..100
10089
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (3) in the Biotechnology industry is significantly better than the same rating for CRNX (90) in the Pharmaceuticals Major industry. This means that REGN’s stock grew significantly faster than CRNX’s over the last 12 months.

REGN's Profit vs Risk Rating (47) in the Biotechnology industry is in the same range as CRNX (53) in the Pharmaceuticals Major industry. This means that REGN’s stock grew similarly to CRNX’s over the last 12 months.

REGN's SMR Rating (54) in the Biotechnology industry is somewhat better than the same rating for CRNX (96) in the Pharmaceuticals Major industry. This means that REGN’s stock grew somewhat faster than CRNX’s over the last 12 months.

REGN's Price Growth Rating (64) in the Biotechnology industry is in the same range as CRNX (83) in the Pharmaceuticals Major industry. This means that REGN’s stock grew similarly to CRNX’s over the last 12 months.

REGN's P/E Growth Rating (89) in the Biotechnology industry is in the same range as CRNX (100) in the Pharmaceuticals Major industry. This means that REGN’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXREGN
RSI
ODDS (%)
Bullish Trend 3 days ago
88%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
71%
Momentum
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
53%
MACD
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
65%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 3 days ago
65%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
62%
Declines
ODDS (%)
Bearish Trend 12 days ago
80%
Bearish Trend 11 days ago
52%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
40%
Aroon
ODDS (%)
Bearish Trend 3 days ago
66%
Bearish Trend 3 days ago
62%
View a ticker or compare two or three
Ad is loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
APEI22.550.17
+0.76%
American Public Education
TROW108.490.13
+0.12%
T Rowe Price Group
NOG35.38-0.02
-0.06%
Northern Oil and Gas
BLX38.82-0.38
-0.97%
Banco Latinoamericano de Comercio Exterior SA
SEED2.04-0.06
-2.63%
Origin Agritech Limited

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with ELVN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then ELVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
+0.71%
ELVN - CRNX
49%
Loosely correlated
-1.96%
ARWR - CRNX
47%
Loosely correlated
-0.57%
ATXS - CRNX
47%
Loosely correlated
-2.57%
DYN - CRNX
46%
Loosely correlated
+1.23%
TRDA - CRNX
45%
Loosely correlated
+0.54%
More

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with IDYA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
+1.64%
IDYA - REGN
41%
Loosely correlated
+5.18%
TECH - REGN
39%
Loosely correlated
-0.47%
VRTX - REGN
37%
Loosely correlated
+1.82%
CRNX - REGN
37%
Loosely correlated
+0.71%
ACLX - REGN
37%
Loosely correlated
+3.67%
More